The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

ABSTRACT:

Introduction

Aspirin, clopidogrel, prasugrel and ticagrelor are antiplatelet agents for the prevention of ischemic events in patients with acute coronary syndromes (ACS), percutaneous coronary intervention (PCI) and other indications. Variability in response is observed to different degrees with these agents, which can translate to increased risks for adverse cardiovascular events. As such, potential pharmacogenetic determinants of antiplatelet pharmacokinetics, pharmacodynamics and clinical outcomes have been actively studied.

Areas covered

This article provides an overview of the available antiplatelet pharmacogenetics literature. Evidence supporting the significance of candidate genes and their potential influence on antiplatelet response and clinical outcomes are summari

SUBMITTER: Yang Y 

PROVIDER: S-EPMC4829114 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature